Summary
62 / 100 · Bulios Score
What speaks for it
- Revenue grew by 19% a year over the last 3 years.
- Out of every 100 INR of revenue, 11 INR is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.8 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (INR)
Diluted EPS (INR)
Revenue grew by 9.6% a year over 5 years. Over the last 3 years it grew by 19% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 INR of revenue goes
- Cost of sales 73 INR
- Sales and administration 9.4 INR
- Taxes and other 5.8 INR
- Net profit 11 INR
Net profit, industry median (Drug Manufacturers - General) 14 INR
Out of every 100 INR of revenue, 11 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.09%
- Paid out of profit
- 3.7%
You receive ₹0.40 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail